^
    1d
    Antibiotic Irrigation and Suction Ureteral Access Sheath in RIRS (clinicaltrials.gov)
    P=N/A, N=180, Not yet recruiting, Hitit University
    New trial
    1d
    Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population (clinicaltrials.gov)
    P=N/A, N=690, Completed, Qilu Hospital of Shandong University
    New trial
    2d
    Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=450, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    2d
    Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=267, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    6d
    Activation of c-Myc confers resistance to venetoclax via inhibition of Bim in t(8;21)-positive acute myeloid leukemia. (PubMed, Cell Commun Signal)
    c-Myc activation is a key driver of VEN resistance in t(8;21) AML. HHT acts as a mechanistically complementary agent, restoring VEN sensitivity. These results provide a preclinical rationale for clinical evaluation of VEN-HHT combination therapy in genetically defined AML subsets.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2L11 (BCL2 Like 11)
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    6d
    Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Medstar Health Research Institute
    New P1 trial
    7d
    Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Dongguan People's Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • Synribo (omacetaxine mepesuccinate)
    8d
    COBRA: Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis (clinicaltrials.gov)
    P=N/A, N=410, Completed, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Jun 2026
    Trial completion • Trial completion date
    9d
    Extended Interval Dosing of Gentamicin in Neonates (clinicaltrials.gov)
    P=N/A, N=42, Recruiting, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Not yet recruiting --> Recruiting | Trial completion date: May 2026 --> Apr 2027 | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    13d
    Evaluation of Efficacy and Safety Parameters of Different Antibiotics Regimens for Management of Empyema (clinicaltrials.gov)
    P=N/A, N=80, Completed, Fayoum University | Recruiting --> Completed | Trial completion date: May 2025 --> Jun 2026 | Trial primary completion date: Apr 2025 --> May 2026
    Trial completion • Trial completion date • Trial primary completion date
    13d
    Astrocytic Phenotypic Switching in Posterior Piriform Cortex Orchestrates Bone Cancer Pain-Depression Comorbidity via Purinergic-Noradrenergic Signaling. (PubMed, Adv Sci (Weinh))
    Interventions targeting astrocyte phenotypes, including minocycline and Lcn2 knockdown, normalized the posterior piriform cortex neurochemistry and alleviated both nociceptive and affective symptoms. These findings define a mechanistic framework in which astrocytic dysfunction orchestrates pain and depression, and highlight astrocyte-directed strategies for treating cancer pain-depression comorbidity.
    Journal
    |
    ADORA2A (Adenosine A2a Receptor)
    |
    minocycline
    14d
    Integrated virulence-resistance profiling of Helicobacter pylori reveals context-dependent pathogenic signatures in gastric cancer. (PubMed, Front Cell Infect Microbiol)
    Two dominant H. pylori molecular states were identified: a virulence-competent Colonizer profile (127/158, 80.4%) enriched for cagA/vacA gene carriage and expression (q < 0.001), and a putative Resistant Inflammatory profile (31/158, 19.6%) characterized by elevated iceA expression (q = 0.002) and clarithromycin resistance mutations (q = 0.022), with reduced cagA/vacA (q < 0.001)...Integrated profiling suggests that H. pylori adopts distinct molecular states in gastric cancer associated with specific clinicopathological features. These findings support systems-level microbial characterization as a hypothesis-generating framework for exploring whether microbial molecular states may contribute to future risk stratification and eradication strategies in AMR-endemic regions, pending functional and external validation.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)